MDSCs appear to be highly sensitive to PARP inhibition, and studies have shown that using the PARP-1 inhibitor olaparib can downregulate the immunosuppressive function of colon cancer MDSCs and enhance the efficacy of anti-PD-1 immunotherapy. Here, PDCD1 is linked to colonic neoplasm.